The San Francisco Board of Supervisors has unanimously voted to decriminalize psychedelics like psilocybin and ayahuasca.
Most American psychiatrists view psilocybin and ketamine as safer drugs than alprazolam (Xanax), methamphetamine, or alcohol, according to a new survey.
A psychedelic drug experience may alter people’s perspectives on death and dying in a similar way to those who have survived a near-death experience, a new study has found.
The first controlled trial of psilocybin for alcohol use disorder (AUD) reports that psilocybin-assisted psychotherapy significantly reduces the occurrence of heavy drinking days in people with AUD.
By studying human brain organoids — tissue cultures grown from stem cells that can mimic the developing brain — researchers have found that LSD regulates numerous processes related to neuroplasticity in the human brain.
By demonstrating that ketamine induces only a brief increase in dopamine and does not alter neuronal communication, a team from the University of Geneva suggests that its therapeutic use may be safe.
PSIL-001 and PSIL-002 show promising antidepressant effects without hallucinations while having improved learning and memory tendencies over a psilocybin mimic in a mouse model.
Dr Stephen Wright, a consultant in medicines development from Limber Strategic, explores the research behind ketamine.
The microdosers in the study generally reported less depression, stress, and anxiety after one month of use, compared to their non-microdosing peers.